Coming Soon

Keith Quencer, MD, completed his diagnostic radiology residency at Massachusetts General Hospital, followed by a fellowship in Vascular and Interventional Radiology at Yale-New Haven Hospital. His clinical interests include renal cell carcinoma, trauma interventions, venous sampling, dialysis access interventions and portal hypertension. He enjoys spending time with family, mountain biking and hiking.

Dr. Parikh’s clinical area of focus is the utilization of minimally invasive techniques to treat patients with benign and malignant tumors within the Gastrointestinal (GI) and Genitourinary (GU) system. Dr. Parikh primarily treats patients with benign prostatic hyperplasia (BPH), prostate cancer and kidney cancer as well as primary and secondary liver cancer. As a widely recognized expert on the utilization of prostate artery embolization (PAE) for the management of patients with prostate cancer, Dr. Parikh is dedicated to advancing innovative oncologic care and founded the PAE program at Moffitt Cancer Center to help men who suffer from decreased urinary function. He has also published several manuscripts on the topic and currently serves as the primary investigator for a clinical trial studying the role of neoadjuvant PAE prior to definitive radiotherapy for men with prostate cancer (https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-20832/).Dr. Parikh has also served in several leadership roles at Moffitt and presently serves as the Assistant Chief Medical Officer. In this role, he uses his prior business experience to serve the institution with a focus on finance, strategy, digital innovation and clinical partnerships.Dr. Parikh earned his undergraduate degree from Columbia University in New York City and subsequently worked as an investment banker on Wall Street. Determined to make a significant impact on the daily lives of patients, he obtained MD and MBA degrees from Tufts University School of Medicine in Boston, MA. He then completed diagnostic radiology residency at NYU Medical Center in New York City, before moving back to Boston to complete a fellowship in Angiography and Interventional Radiology at the Brigham and Women’s Hospital – Harvard Medical School.

Clinical Assistant Professor, Department of Radiology at NYU Grossman School of Medicine

Board Certifications
American Board of Radiology – Interventional Radiology & Diagnostic Rad, 2021

Education and Training
Residency, University of Pennsylvania Health System, Interventional Radiology, 2020
Residency, University of Pennsylvania Health System, Diagnostic Radiology, 2017
MD from SUNY-Downstate, 2014

Nadia Nocera, M.D., is a breast surgical oncologist at Baptist Health Cancer Care. Dr. Nocera specializes in treating breast cancer. She is fluent in English and conversational in Spanish and Italian.

Prior to joining Baptist Health Cancer Care in 2021, Dr. Nocera completed a fellowship in breast surgical oncology at the H. Lee Moffitt Cancer Center in Tampa.

Dr. Nocera is a proud first-generation college graduate. She has been involved with dendritic cell vaccine research for breast cancer and melanoma. Her research has been published in peer-reviewed publications, including the Annals of Surgical Oncology, the Journal of Surgical Education, Immunotherapy and Frontiers in Pharmacology. She has also presented at numerous medical conferences, including the American Society of Breast Surgeons Annual Meeting and the Miami Breast Cancer Conference.

Dr Modi is a consultant radiologist who specializes in clinical and interventional radiology (image-guided medical treatments).
BSc (Hons) MBBS FRCR FRCR(IR)

Training and education
Undergraduate medical training – St George’s, University of London
Bachelor of science (BSc) – St George’s, University of London
Postgraduate training in clinical radiology, West Midlands Deanery
Postgradute subspecialist training in interventional radiology – West Midlands Deanery
Interventional radiology fellowship – McGill University, Montreal, Canada

Sir Michael Brady was appointed half-time as Professor of Oncological Imaging in the Department of Oncology at the University of Oxford, having retired from his 25-year Professorship in Information Engineering in 2010. After obtaining degrees in mathematics, he worked in computing science, artificial intelligence, and engineering. He founded the Oxford University Robotics Group, but switched his interests to cancer image analysis in the early 1990s.

Apart from his Oxford research, Mike has founded a number of companies, including Matakina and ScreenPoint (mammographic image analysis), Mirada Medical (medical image fusion), and Perspectum Diagnostics (liver MRI).

He is a member of CRUK’s Science Committee and chairs the Multidisciplinary Expert Review Panel and the Royal Society Publications Board. He is a Fellow of the Royal Society.

Manuel Ozambela, Jr., M.D., is a urologic surgical oncologist at Baptist Health Miami Cancer Institute. He specializes in the treatment of cancers that arise from the genitourinary system (urinary and reproductive systems), including kidney, bladder, prostate, testicular and penile cancers. He is fluent in English and Spanish. After earning his medical degree from Harvard Medical School, Dr. Ozambela completed his urologic surgery training at Brigham and Women’s Hospital in the Harvard Program in Urology. He received both the Exceptional Resident Award and the Award in Academic Excellence for his outstanding clinical performance and academic achievements.

Prior to joining Baptist Health, Dr. Ozambela completed his fellowship in urologic oncology at the University of Texas MD Anderson Cancer Center. During the fellowship, he worked with a multidisciplinary group of investigators to study rare and aggressive kidney tumors with the goal of identifying novel treatment options. He has authored multiple scientific abstracts, manuscripts and book chapters on various topics in urologic oncology. Through his research, he strives to identify new diagnostic and treatment options for genitourinary cancers, improve patient recovery after surgery and enhance his patients’ quality of life.Understanding that he often meets patients during significantly stressful moments, Dr. Ozambela takes time to talk through diagnoses and treatment options. Through excellent communication and shared decision-making, he works with his patients to create treatment plans that reflect their individual goals. Dr. Ozambela is a South Florida native and enjoys spending time with his growing family when not taking care of patients.

Charles Martin III, MD, is a Cleveland Clinic interventional radiologist. He subspecializes in interventional oncology, minimally invasive/percutaneous cancer therapies, hereditary hemorrhagic telangiectasia, pulmonary arteriovenous malformation embolizations and embolotherapy. Beyond his clinical experience, Dr. Martin is actively engaged in research, and has led or served as co-investigator on multiple clinical studies. He is passionate about innovating new devices for interventional radiology and investigating technologies capable of better engaging patients or developing more effective and more efficient procedures.

Dr. Pilar Bayona Molano is a Clinical Associate Professor at the University of Miami, specializing in interventional radiology with special dedication in the field of interventional oncology. She actively participates in tumor boards, offering valuable insights into locoregional therapies as primary tools for hepatocellular cancer treatment. Dr. Bayona is a speaker, and contributor to key journals and conferences in the field.

Alan Sag, MD is a Vascular and Interventional Radiologist at the University of Miami with special expertise in embolization and ablation, as well as musculoskeletal, pain, and thyroid interventions

Mark graduated from Oxford Medical School in 1994 and worked in London before completing radiology training at Oxford.
He has undertaken the Ratcliffe Fellowship in thermal ablation at University College Hospital, London and a fellowship in oncological imaging in Oxford. He was appointed consultant in 2008 and is the Clinical Lead for the Thermal Ablation Service. In addition to his clinical commitments, he has an active research interest in thermal ablation and the use of functional imaging techniques to understand the behavior of tumors and select appropriate therapies for patients.

Professor Chiara Floridi is an associate Professor and 10-year experienced interventional radiologist at Università Politecnica delle Marche,Italy. Professor Floridi earned her medical degree and residency from the University of Perugia, Italy. She completed her training with a fellowship in interventional radiology at the University of Insubria in Varese. In 2016, she moved to interventional radiology unit of University of Milan. She then joined Azienda Ospedaliero-Universitaria delle Marche of Ancona, where she currently holds the position of associate Professor since 2020.Her leading clinical interests include minimally invasive CT-guided interventions, vascular and extra-vascular procedures, with specific expertise in oncological interventions, including but not limited to hepato-biliary field. She is also a member of the multidisciplinary liver transplant team of Azienda Ospedaliero-Universitaria delle Marche. Her research interests include fusion and functional imaging during image-guided procedures, and well-established and innovative therapeutic locoregional treatments for primary and metastatic liver cancers. Prof. Floridi is a fellow of the European Cardiovascular and Interventional Radiological Society (CIRSE) and of Italian Society of Medical and Interventional Radiology (SIRM), where she currently serves the position of Chair of the Computed Tomography Sub-speciality. She is deputy editor of La Radiologia Medica, official Journal of the Italian Society of Medical and Interventional Radiology.

Dania Daye, MD, PhD is an interventional radiologist at Massachusetts General Hospital and faculty member at Harvard Medical School and at the MGH/HST Martinos Center for Biomedical Imaging. Her clinical interests are in venous disease, interventional oncology, tumor ablation and MRI-guided interventions. She holds a number of leadership positions in regional and national radiology professional societies. Locally, Dr. Daye is the interventional radiology division Quality Director and the co-Director of IR Research. Dr. Daye is passionate about care delivery redesign and patient-centered care in radiology. Dr. Daye designed the James H. Thrall Management and Leadership Training (MLT) Program for radiology residents, is founding co-chair of the Women in Radiology Steering Committee at MGH and current co-chair of the MGH Department of Radiology Diversity, Equity and Inclusion Committee.

Professor Roberto Iezzi, a pioneer in Diagnostic and Interventional Radiology, is dedicated to advancing Interventional Oncology as a discipline. Specializing in a wide array of areas, including Oncological Interventional Radiology, Cardiovascular Imaging, Emergency and Urogenital Interventional Radiology, Prof. Iezzi’s expertise is unmatched.

Currently, Prof. Iezzi leads the Emergency and Interventional Radiology Unit at the Università Cattolica del Sacro Cuore – Fondazione Policlinico A. Gemelli in Rome, which was accredited by IASIOS in 2022. He also serves as an associate professor at the Catholic University of the Sacred Heart in Rome. His contributions extend globally, as he actively participates in multidisciplinary boards and serves on Editorial Boards of esteemed journals.

Dr Finn is a Professor of Clinical Medicine in the Division of Hematology/ Oncology at the UCLA David Geffen School of Medicine and Director of the Signal Transduction Program in the Jonsson Comprehensive Cancer Center at UCLA.

He currently splits his time between patient care and laboratory and clinical research. His research interests lie in the development of molecular targeted agents and biomarkers in liver cancer and breast cancer. Dr Finn has served as principal and sub-investigator in trials exploring the use of targeted therapies in breast and hepatocellular cancers. He has a particular interest in identifying predictive markers of response to novel therapeutics. His work has been published in journals such as the New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Lancet Oncology, Cancer Research, Clinical Cancer Research, Hepatology, Cancer Cell and elsewhere. Dr Finn has also given oral presentations at major meetings including American Society of Clinical Oncology (ASCO), European Cancer Conference (ECCO/ ESMO), and the American Association of Cancer Research (AACR) and others. An active cancer researcher, he has been involved in the development of several novel therapeutics in cancer medicine. He has brought several practice changing advances to cancer medicine. He played a lead role in the approval of palbociclib (Ibrance), the first CDK 4/6 inhibitor in cancer medicine, from pre-clinical development to global registration and more recently the combination of atezolizumab and bevacizumab for the treatment of advanced liver cancer.

Dr Finn is a member of ASCO, American Association of Cancer Research (AACR) and the European Society of Medical Oncology (ESMO). He is a past president of the International Liver Cancer Association (ILCA). He is on the editorial board of Clinical Cancer Research.

Robert J. Lewandowski, M.D., FSIR, is a Professor of Radiology, Medicine, and Surgery in the Feinberg School of Medicine at Northwestern University. He serves as the Director of Interventional Oncology at the Northwestern University Robert H. Lurie Comprehensive Cancer Center. Dr. Lewandowski joined the staff at Northwestern in 2006 upon completion of his fellowship training in Vascular and Interventional Radiology. Dr. Lewandowski is a practicing interventional radiologist who specializes in liver-directed therapy. Based on his clinical oncology program, he has authored or co-authored > 150 articles for peer-reviewed journals on the application of liver-directed therapies for patients with gastrointestinal malignancies. Dr. Lewandowski also performs pre-clinical oncology research in the Northwestern University Interventional Oncology Laboratory and Center for Translational Imaging. In this capacity, he is developing and evaluating novel oncology therapeutics, delivery mechanisms, and imaging modalities. Dr. Lewandowski’s work has been supported by the National Institute of Health, American Cancer Society, the Society of Interventional Radiology Foundation, and through industry collaboration via the investigator-initiated trial mechanism.

Dr. Dimitrios Filippiadis serves as Associate Professor of Diagnostic and Interventional Radiology at the Medical School of National and Kapodistrian University of Athens. His work has resulted in over 160 scientific publications, hundreds of scientific and business presentations, 34 book chapters, and substantial industrial grant support. He is a CIRSE Fellow and the recipient of more than 15 major honors/awards. Dr. Filippiadis has served in the scientific program committees of CIRSE, ECIO, SIO, ECR,RSNA and in the Editorial Board of major journals including CVIR. Currently Dr. Filippiadis serves as Chairman of CIRSE’s Online Education Committee

Hicham Kobeiter has been working as an Interventional Radiologist at University Hospital CHU Henri Mondor Creteil, France for the past 15 years. For the last 6 years, he is the Chief of the Vascular and Oncology Interventional Unit in the Radiology Department.

Dr. Kobeiter’s clinical and research topics are Aortic and Aneurismal Pathology and Multimodality Image-Guided Therapy. He was a dedicated Professor in Hôpital Henri Mondor, Creteil, France from 2007 to 2013. Dr. Kobeiter is also President of the French Society of Cardio-Vascular and Interventional Radiology SFICV.

Keith Quencer M.D. is an interventional radiologist at OHSU with particular interest in GU interventions including renal ablation, adrenal vein sampling and dialysis interventions.

Riccardo Lencioni is Professor of Radiology at the University of Pisa School of Medicine in Pisa, Italy, and the Director of the Cancer Imaging Program at the Department of Radiology and Nuclear Medicine of Pisa University Hospital. He is also the Vice President for Medical Education at the University of Pisa and an Honorary Research Professor of Interventional Oncology at the Miami Cancer Institute in Miami, USA. Riccardo Lencioni is known especially for his highly influential research work in liver cancer. He has been a leading member of several expert panels developing recommendations for research and clinical management of hepatocellular carcinoma. He is also known for having established modified RECIST criteria for the assessment of tumor response in hepatocellular carcinoma. Riccardo Lencioni has been the Founding Chairman of the European Conference of Interventional Oncology, a co-Founder and Chairman of the World Conference of Interventional Oncology, and a Founding Governing Board Member and Executive Secretary of the International Liver Cancer Association. He is currently the Co-Director of the SPECTRUM Interventional Oncology Multidisciplinary Conference. Professor Lencioni has published over 230 articles in peer-reviewed international journals indexed in PubMed and numerous chapters in textbooks of interventional radiology, gastroenterology, oncology and surgery. In addition, he has been the editor of 12 books. According to SCOPUS, citations of his publications currently exceed 37,000, for an h-index of 77.

Dr. Sze is professor of Radiology (Interventional Radiology) and practices at Stanford Health Care, Stanford Medicine Children’s Health.  His clinical focus includes cancer, interventional radiology, interventional oncology, interventional radiology and diagnostic radiology.

Dr. Starr Mautner is a board-certified and fellowship-trained breast surgical oncologist at the Miami Cancer Institute where she treats patients with benign and malignant breast disease.  She earned her medical degree from the University of Miami Miller School of Medicine and completed a general surgery residency at New York Presbyterian Hospital-Weill Cornell Medical College. She then went on to complete a research and clinical fellowship in breast surgical oncology at Memorial Sloan Kettering Cancer Center in New York before moving back to Miami to join the Miami Cancer Institute in 2015. Dr. Mautner is the lead physician for breast surgery clinical trials at MCI and is active in clinical research.  She is also the co-chair of the Memorial Sloan Kettering Cancer Center Alliance Education Committee and is very involved in community engagement and educational programs.  

Dr. Saeed Sadeghi is a hematologist and medical oncologist who practices in Santa Monica. He is a generalist that cares for patients with all types of cancer, with a specialized interest in breast,  gynecological and hepatobiliary cancers. He is board certified in internal medicine, hematology, and medical oncology. Dr. Sadeghi participates in UCLA Health’s full suite of clinical trials and has
served as a principal investigator on clinical trials for breast and hepatobiliary cancers. His treatment philosophy is to provide wraparound, whole patient care, which may include social emotional support from the Simms/Mann Center for Integrative Oncology, and complementary alternative therapies, such as acupuncture and supplements.

Dr. Sadeghi received his medical degree from the St. Louis University School of Medicine. He then completed his internal medicine residency at the Los Angeles County + USC Medical Center, followed by his hematology-oncology fellowship at UCLA. He also received his Bachelor of Science degree from UCLA. In addition to his clinical work, Dr. Sadeghi is a clinical professor in the
Division of Hematology-Oncology at the David Geffen School of Medicine at UCLA. He is also a board member of the Persian American Cancer Institute, and a member of the American Medical Association, American Society of Hematology, and American Society of Clinical Oncology, among other professional organizations.

Graduated in Medicine from Universidade Estácio de Sá (2010), specialization in Fellow Interventional Radiology from the National Cancer Institute (2017), specialization in Radiology from the University of São Paulo (2015), Master’s degree in Medicine (Radiology) from the Federal University of Rio de Janeiro (2015), medical residency at the Federal University of Rio de Janeiro (2014) and medical residency at the National Cancer Institute (2015). He has experience in the field of Medicine, with an emphasis on Medical Radiology.

Dr. Breelyn A. Wilky, MD is a sarcoma medical oncologist and clinical trialist with research interests in immunotherapy, targeted therapy and precision medicine, and early phase drug development. She is Associate Professor and Director of the Sarcoma Program at the University of Colorado School of Medicine, and also holds the The Cheryl Bennett and McNeilly Family Endowed Chair in Sarcoma Research. As the Deputy Associate Director of Clinical Research for the University of Colorado Cancer Center, she leads the investigator-initiated clinical trials committee to help advance novel research to the clinic. Her laboratory studies the tumor and immune microenvironment of sarcomas, to identify new drugs that boost the immune system for future clinical trials.

Dr. Wilky received her undergraduate degree in Biology and Music from Bates College in Lewiston, Maine, and attended medical school at the University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School in Piscataway, New Jersey (now Rutgers Medical School.) She received her MD with Distinction in Research. She then completed the Osler internship and residency in Internal Medicine at The Johns Hopkins Hospital in Baltimore, Maryland, and stayed on to complete her fellowship in Medical Oncology. Her honors and awards include election to the Alpha Omega Alpha Honor Medical Society, an ASCO/Conquer Cancer Foundation Young Investigator Award in2012, the 2017 Outstanding Clinical Researcher of the Year at Sylvester Comprehensive Cancer Center at the University of Miami, and is the prior recipient of an American Cancer Society Mentored Research Scholar Grant.

I am a senior consultant interventional radiologist with special interest in both imaging and interventional oncology. Interventional Oncology (IO) is the emerging clinical discipline and is beginning to establish as the 4th pillar of cancer care alongside surgical, clinical, and medical oncology. Since 2003, I have led and developed the IO clinical and research program at the LTHT using various technologies e.g., radiofrequency (RFA), microwave ablation(MWA), cryoablation (CRYO) and irreversible electroporation (IRE) for a range of cancers such as liver, lung, renal, pancreas, adrenal, spleen etc. Today, Leeds is one of the leading national and international IO centers with reputable clinical outcomes and provides a full complement to innovative technologies such as RFA, MWA, CRYO and IRE for cancer treatment. I am one of the pioneers and leading interventional radiologists in the UK with a vast amount of clinical experience in renal ablative therapy. I am committed to drive clinical and research excellence in IO and have led and participated in grant funding research and lectured extensively on IO related topic to help to promote awareness and providing mentoring schemes to many trainees and consultants in IO on national and international levels since 2003.In addition, I am a passionate champion for female leadership and love to inspire more women into Interventional Radiology. I have strived to inspire all male and female IRs to help in closing the IR gender gap issue in Europe. The publication on IR Gender Gap work that I co-authored with the support of CIRSE has received worldwide recognition and engagement within the IR community to create the change that is needed titled-The Interventional Radiology (IR) Gender Gap: A Prospective Online Survey by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) and the publication can be downloaded athttps://www.ncbi.nlm.nih.gov/pubmed/29789874.I co-led and facilitated the RCR publication (2020) on women in Interventional Radiology-insights into subspecialty.

More locally in Leeds and Yorkshire. I have founded YiiRS with the IR training program director and tutor to raise awareness in Imaging and interventional Radiology and hopefully to inspire the medical students and next generation of doctors to pursue this exciting career.

Thomas Scagnelli, M.D. joined Miami Vascular Specialists in 2009 after having served as an Associate Professor of Interventional Radiology at the University of Florida College of Medicine, and prior to that, at the University Of Miami School Of Medicine, where he was involved in the training of numerous resident physicians and fellows in Vascular and Interventional Radiology. He presently serves as a Voluntary Associate Professor of Interventional Radiology at the University Of Miami School Of Medicine. He is currently the Medical Director of Interventional Radiology and the Associate Director of Diagnostic Radiology at Doctor’s Hospital, Baptist Health South Florida in Coral Gables, Florida. Dr. Scagnelli is a native of Brooklyn, New York having attended Xaverian High School in Bayridge Brooklyn and Rutgers University in New Brunswick, New Jersey. He received his Medical Degree from CETEC University School of Medicine in Santo Domingo. He completed an Internship in Internal Medicine and a combined residency in Diagnostic Radiology and Nuclear Medicine at the Long Island College Hospital in Brooklyn, New York and a fellowship in Vascular and Interventional Radiology at the University Of Miami School Of Medicine. Dr. Scagnelli serves as a board examiner for the American Board of Radiology(ABR) for both the Board Examinations in Diagnostic Radiology and Vascular and Interventional Radiology. He is a member of the Society of Interventional Radiology (SIR) and serves on the SIR membership committee. He is also a member of the Radiological Society of North America (RSNA), for which he has monitored many scientific sessions at its annual meeting, and is also a member of the American College of Radiology (ACR). He also serves as a member of, and advisor to, the Vascular and Interventional Examination Committee for the American Registry of Radiologic Technologists (ARRT).

Dr. Scagnelli has participated in multiple clinical research projects involving inferior vena cava filters, transarterial chemoembolization procedures, endovascular repair of arterial trauma, transhepatic portosystemic shunt procedures in treatment of intractable ascites, and transjejunal and conventional biliary tract intervention .Dr. Scagnelli is Board-certified in Diagnostic Radiology with a Certificate of Added Qualification in Vascular and Interventional Radiology from the American Board of Radiology (ABR)

Caio Max S. Rocha Lima, M.D. is the M. Robert Cooper Professor in Medical Oncology. He is the Co-leader GI Oncology and Co-leader Phase I Programs at the Division of Hematology and Oncology at Wake Forest School of Medicine in Winston-Salem, NC. Prior to join Wake Forest School of Medicine, Dr. Rocha Lima was the Associate Cancer Center Director for Translational Research Gibbs Cancer Center & Research Institute and CMO Guardian Research Network Dr. Rocha Lima received his medical degree from the Federal University of Bahia-Salvador and later pursued residency training at the Clinical Hospital of Sao Paulo University; both in his native country of Brazil. Afterwards Dr. Rocha Lima completed a fellowship in hematology/oncology at the Medical University of South Carolina. Dr. Rocha Lima was an assistant Professor of Medicine at Moffitt Cancer Center in Tampa, Fl. As a full Professor, at the University of Miami, he was the Program Co-Leader for Pancreatic/Hepatobiliary and Colorectal Cancer Site Disease Groups. He also co-lead the Phase I program at the University of Miami. Dr. Rocha Lima’s professional memberships include the American Society of Hematology, The American Society of Clinical Oncology, the East Cooperative Oncology Group, and the European Society of Medical Oncology, where he served as the USAASCO representative in 2002-2003.Dr. Rocha Lima has engaged in a considerable number of studies that investigate the use of novel agents to treat solid tumors, including pancreatic cancer, lung cancer, and colorectal cancers. He was frequently involved as a principal or co-investigator in many clinical trials including the PI of a phase III trial that involved the Americas, Asia and Australia in Pancreas cancer. Dr. Rocha Lima’s research has been widely published in journals such as Journal of Clinical Oncology, Chest, Oncology, Seminars in Oncology, Cancer, and The Annals of Oncology.

William S. Rilling, MD, FSIR is a Tenured Professor of Radiology and Surgery at the Medical College of Wisconsin. He completed his diagnostic radiology residency at the Medical College of Wisconsin and his Fellowship in Vascular Interventional Radiology at Northwestern University in Chicago in 1996. Hehas been practicing at the Medical College of Wisconsin since 1996 and is the Vice Chair of Clinical Operations in Radiology and the former Chief of the Division of Vascular and Interventional Radiology for14 years. Dr. Rilling has served on the Executive Council for the Society of Interventional Radiology (SIR), and the Board of Directors for both the World Congress of Interventional Oncology (WCIO) and SIR Foundation. As Education Councilor for SIR, he co-directed the first three professional education meetings dedicated to Interventional Oncology beginning in 2002. He has also served as the annual meeting chair for both SIR and WCIO and is the past-president for the Society of Interventional Oncology (SIO). He has served as local and national principal investigator for several important IO trials and is currently active as a consultant for several companies working to improve outcomes in IO.

Dr. Reshma Mahtani serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (a Memorial Sloane Kettering affiliate). She specializes in the treatment of breast cancer. Prior to assuming her role at the Miami Cancer Institute, Dr. Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She is an active clinical researcher, and her research focuses on novel therapies for the treatment of breast cancer. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals. She has served on the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative (QOPI) Steering Committee and as a member of the editorial board of The Breast Journal. She is the Editor-in-Chief of Practice Updates (an online medical education platform for physicians). She is on the Board of Directors for LBBC (Living Beyond Breast Cancer). She has a passion for medical education and founded a medical education initiative to ensure that physicians in South Florida know about the latest cancer treatments and can provide evidence-based care. Finally, she is involved in several initiatives that enhance patients’ access to healthcare and community collaborations for education and advocacy.

David M.Liu, MD is a board certified in both Canada and the US, practicing at the Vancouver General Hospital, University of British Columbia Hospital and the BC Cancer Agency with a cross appointment in the Department of Surgery. Dr. Liu received his medical degree from University of Toronto, completed his radiology residency at University of British Columbia, Interventional Radiology fellowship at Northwestern Memorial Hospital, and has practiced in both the US and Canada. In addition to bench side and clinical research in the fields of novel embolic platforms, ablative technologies and cancer related thromboembolic disease, Dr. Liu maintains an interventional oncology practice incorporating all aspects of embolization, ablation, venous access, and palliative therapy in all organ systems. He is the co-founder and co-chair of the international liver cancer symposium, SHOW, and has been credited with 7 book chapters, over 70publications, and over 100 invited lectures around the world. Dr. Liu an active member of the interventional radiology community as recognized through his induction as a Fellow of the Society of Interventional Radiology and has been awarded the CIRA award from the Canadian Association of Interventional Radiology (CAIR) in recognition of his extraordinary contribution to the practice of IR in Canada and worldwide

Fred T. Lee Jr., MD is Professor of Radiology, Biomedical Engineering, and Urology, and the Robert A. Turrell Professor of Imaging Science at the University of Wisconsin Department of Radiology. Dr. Lee has special interests in cancer imaging and interventions with an emphasis on percutaneous tumor ablation. His work has resulted in nearly 300 scientific publications,22book chapters, greater than70 major awards including multiple “Best Doctor” awards, 25patentsand inventions, and substantial federal and industrial grant support. Dr. Lee is a founder of two venture-backed medical device companies: Elucent Medical, Inc., and NeuWave Medical Inc., a University of Wisconsin spin-off company which sold to Ethicon (Johnson &Johnson) in 2016, and is a board member and Senior Medical Advisor for Histosonics, Inc., a University of Michigan spin-off company. Dr. Lee will be awarded the Gold Medal for the Society of Interventional Radiology in March 2024

Dr Landinez is an interventional radiologist with a keen interest in palliative care, and musculoskeletal interventions. Most recently she has spent time at MD Anderson Cancer Center, where she completed fellowship, as well as UCSF where she practiced up until her joining the Miami Cancer Institute and Miami Cardiovascular Institute

Dr. Brian E. Lally is a radiation oncologist in Charleston, South Carolina and is affiliated with multiple hospitals in the area, including Pennsylvania Hospital and Doylestown Hospital. He received his medical degree from Sidney Kimmel Medical College at Thomas Jefferson University and has been in practice for more than 20 years.

Dr. Oleksandra Kutsenko is an interventional radiologist at Red Rock Radiology Associates, a prominent private practice group that leads in providing advanced IR care to oncologic patients in the state of Nevada. Dr. Kutsenko attained her medical degree with the highest honors from the University of Lublin. After completing her diagnostic radiology residency at SUNY Upstate University Hospital, she graduated as an IR Chief resident from Miami Cardiac and Vascular Institute. Dr. Kutsenko has published multiple scientific papers, authored textbook chapters, and presented her research at national and international meetings. She is actively involved with theIR community and currently serves on SIR Economics Committee, Comparative Effectiveness Research Committee, Women’s Health Council, and Carrier Advocacy Workgroup. She is highly motivated in promoting minimally-invasive medicine. Among her projects, a TEDx talk “Believe in Better Medicine”

Professor of Radiology, Division of Interventional Radiology. Medical Director for Supply Chain and Value Based Care. Clinical and Research interests are locoregional options for primary and secondary liver tumors and renal tumors. Interests in emerging therapies, especially ablative technologies

Dr. Koethe is an interventional radiologist at TRG Imaging in Portland, OR. She is also proud to have been the former Director of Interventional Oncology and Assistant Professor at Oregon Health & Science University. She is the vice chair of the Early Career Section of the Society of Interventional Radiology and is a member and volunteer at the Society of Interventional Oncology and at the American Board of Radiology. She specializes in interventional oncology and musculoskeletal interventions.

Ramon E. Jimenez, M.D., FACS, is a surgical oncologist and chief of the Division of Melanoma and Soft Tissue Sarcomas at Miami Cancer Institute. He has been in practice for more than 20years and has extensive experience in the surgical management of complex tumors. His areas of expertise include melanoma, soft tissue sarcoma, upper gastrointestinal malignancy, and hepatobiliary and pancreatic tumors. Dr. Jimenez collaborates with the Institute’s multidisciplinary team of cancer care specialists, including pathologists, radiologists, medical oncologists, radiation oncologists and patient support specialists, to provide the most effective treatment plan for each individual patient.

Blake B. Jacks, MD is an Interventional Radiologist at CARTI Cancer Center in Little Rock, AR. He completed medical school, internship, and diagnostic radiology residency at the University of Arkansas for Medical Sciences where he was chief resident. He completed an independent interventional radiology residency at Miami Cardiac & Vascular Institute where he was the first chief resident in program history. He focuses on interventional oncologic and palliative minimally invasive procedures. He has presented at national meetings and is published in the medical literature.

Dr. Timothy Huber is an Interventional Radiologist with a focus in interventional oncology and minimally invasive thyroid interventions. Following residency and fellowship in vascular and interventional radiology at the University of Virginia, he established a multidisciplinary thyroid RFA program at Oregon Health and Science University. After returning to the east coast, he has built a thyroid intervention practice at Jefferson Radiology in central Connecticut. He is a founding member of the North American Society for Interventional Thyroidology and speaks regularly on the role of minimally invasive thyroid interventions for benign and malignant thyroid disease. He has authored and co-authored a number of peer reviewed articles on thyroid nodule radiofrequency ablation.

Varshana Gurusamy is a native Texan, who did her undergraduate training at Baylor University. After medical school at Drexel University College of Medicine, in Philadelphia, she returned to Houston to complete her residency at Baylor College of medicine in Houston Texas. She completed her fellowship training at the Miami Cardiac and Vascular Institute. She was associate program Director of the interventional radiology residency at the medical University of South Carolina in Charleston for two years. She is now faculty at MD Anderson, Cancer Center in Houston Texas. Her interests include peripheral vascular and venous disease, interventional, oncology, in particular IRE, and trainee education.

Dr. Afshin Gangi received his education in the International French School of Teheran, graduating in1980. During the summer of 1980, he attended medical school at the University of Reims in France, receiving his Degree in 1987. He began his residency in Strasbourg in 1987, first in the intensive care unit and Pneumology where he became excited about imaging and moved to the imaging department. After his Residency in general radiology and Neuroradiology, he worked one year in Luxembourg with Professor R.F. Dondelinger in Interventional Radiology. Dr. Gangi began his fellowship in Strasbourg in November 1991 in the department of Neuroradiology and MSK with special interest in percutaneous procedures. He performed his first vertebroplasty in 1989during his residency and continued to develop image-guided procedures in interventional oncology, especially under CT-C arm fluoroscopy and MR guidance. In 1995, Dr. Gangi obtained his Ph.D. in Laser Physics in Strasbourg. During the same year, he was appointed Assistant Professor in the University Hospital of Strasbourg and he became a full Professor of Radiology in 2000. Since 2014, he is working in King’s college London for research in interventional oncology and HIFU as an invited Professor with Professor Andy Adam. Prof Gangi holds numerous patents and is an author of more that 300 peer reviewed articles. He has more than 40 book chapters to his credit along with over 500 abstracts at numerous national and international conferences. Currently, Dr. Gangi is the Chairman of Radiology and Nuclear medicine in the University Hospital and work in the department of Interventional Radiology, with a special interest in Interventional Oncology. He is actively involved in different international society and is the past president of Cardiovascular and Interventional Radiological Society of Europe (CIRSE)

Thierry de Baere is professor of medicine at University Paris Saclay, Paris, France and Head of Interventional Radiology at Gustave Roussy Cancer Center. He is full time dedicated to interventional oncology at Institut Gustave Roussy since 1991. Excellent collaboration with surgery and medical oncology teams, active member of tumor board, allowing to develop many synergistic treatments, including optimization of various intra-arterial therapies for primary and secondary liver tumors and locoregional therapies for innovative cancer treatment. He has a long experience in thermal ablation of liver, lung and renal cancers. He has active research in intratumoral immunotherapy.

An internationally recognized expert in radiation therapy for gastrointestinal (GI) cancers, Michael Chuong, MD, FACRO, is Vice Chair and Medical Director of Radiation Oncology and leads the GI radiation service at Baptist Health. Dr. Chuong earned his medical degree from the University of South Florida College of Medicine and completed his residency training in radiation oncology at the H. Lee Moffitt Cancer Center, where he served as the chief resident. He also serves as the Vice Chair of Education and Clinical Research and is Professor of Radiation Oncology at the Florida International University Herbert Wertheim College of Medicine. Dr. Chuong frequently is invited to speak across the globe about his clinical expertise and research that is impacting the standard of care, especially related to proton therapy and MRI-guided radiation therapy. Dr. Chuong has co-authored over 100 peer-reviewed manuscripts in prestigious journals such as JAMA Oncology and the International Journal of Radiation Oncology Biology Physics, for which he is the GI Section Editor. He is a principal investigator for multiple national and international clinical trials that are exploring advanced radiation therapy strategies and unique combinations of radiation therapy with novel therapeutic agents for GI cancers. An active leader in the medical community, Dr. Chuong is the Protocol Monitoring and Review Committee Chair at Baptist Health Miami Cancer Institute, Disease Site Chair of the Proton Collaborative Group and the Particle Therapy Co-operative Group Gastrointestinal Subcommittee Co-Chair. He participates as an active member of the NRG Oncology Non-Colorectal GI Subcommittee, NRG Oncology Pancreas Working Group, NRG Oncology International Liaison Committee and RTOG Foundation Communications Committee

Matthew R. Callstrom, M.D., Ph.D., is a consultant and serves as chair of the Midwest Department of Radiology at Mayo Clinic. Dr. Callstrom is a member of the Mayo Clinic Board of Governors and Board of Trustees. He also serves as an associate medical director in the Department of Development as well as the medical director for the Strategy Department. He joined the staff of Mayo Clinic in2000 and holds the academic rank of professor of radiology, Mayo Clinic College of Medicine and Science. Dr. Callstrom earned his B.S. and Ph.D. from the University of Minnesota, Twin Cities. He completed medical school, radiology residency training and fellowship at Mayo Clinic College of Medicine and Science. As a physician researcher, he has participated in ongoing career and leadership development training.

Yolanda Bryce, MD, RPVI completed her Medical School training at Loma Linda University School of Medicine in 2009, followed by a Diagnostic Radiology Residency at Mount Auburn Hospital in Cambridge, Massachusetts in 2014, a subspecialty training in Breast Imaging at Memorial Sloan Kettering Cancer Center (MSKCC) in 2015, and a Fellowship in Vascular and Interventional Radiology at Miami Cardiac and Vascular Institute in 2016. She joined the faculty at Memorial Sloan Kettering Cancer Center in August 2016 where she probes the intersection of her subspecialties, pioneering minimally invasive cryoablation technique to treat locoregional disease in patients that are poor surgical candidates as well as using innovative multidisciplinary approach to treat metastatic breast cancer. She will conduct a new trial to examine the immune response when pembrolizumab is combined with cryoablation in metastatic triple negative breast cancer. She also specializes in vascular disease in oncologic patients, boarded through the American Board of Vascular Medicine and holding a Registered Physician Vascular Interpretation(RPVI) certification. In 2018, she became the founding director of MSKCC’s Noninvasive Vascular Imaging Center and started the institution’s Peripheral Arterial Disease (PAD) program improving mobility and quality of life of some of the most vulnerable patients–those with both cancer and life-limiting PAD. Her trial examines the benefit of screening for PAD in at-risk cancer patients.

Dr Steve Bandula is an Interventional Oncology Consultant and Associate Professor in Cancer Intervention at University College London (UCL). He trained at Cambridge University, and UCL Hospitals, and was awarded a National Institute for Health Research (NIHR) doctoral fellowship to develop non-invasive tissue characterization. Dr Bandula has a broad interest in focal cancer therapy and leads a busy London Centre treating a range of tumors-including those of the lung, soft tissue, bone, breast, thyroid and prostate. He is a member of the Interventional Oncology UK (IOUK) national committee and runs the Foundation for Interventional and Oncology Research(FIOR)-part of University College Hospital Charitable Trust.

Horacio Asbun, M.D., FACS, is a surgical oncologist and chief of hepatobiliary and pancreatic surgery at Baptist Health Miami Cancer Institute. He is certified in surgical oncology by the American Board of Surgery. He specializes in the treatment of liver cancer, gallbladder cancer, biliary system cancer and pancreatic cancer and diseases. Dr. Asbun received his medical degree from the University of Chile in Santiago de Chile. He completed a general surgery residency at the University of California Affiliated Program in Bakersfield, California. His postdoctoral training includes a general surgery fellowship at Hospital de La Santa Cruz y San Pablo, Barcelona Autonomous University in Spain; a surgical oncology fellowship at the University of California in San Diego; and a fellowship in gastrointestinal, hepatobiliary and pancreas surgery at Lahey Clinic in Burlington, Massachusetts. Prior to joining Baptist Health Miami Cancer Institute, Dr. Asbun served as director of the Hepatobiliary and Pancreas Program and chairman of General Surgery at Mayo Clinic Florida. He was also an adjunct professor of surgery at Mayo Clinic College of Medicine. Dr. Asbun is actively involved in clinical research to improve treatment efficacy and patient outcomes. He has published more than 150 peer-reviewed scientific articles, 110 peer-reviewed surgical videos and35 book chapters in his areas of specialty. He also serves as editor-in-chief of the American College of Surgeons Multimedia Atlas of Surgery and as reviewer for numerous scientific journals. He directs and teaches national courses on surgery and speaks frequently at scientific conferences around the world, with more than 410 presentations to date. In addition to being a fellow of the American College of Surgeons, Dr. Asbun is a member of multiple surgical societies and serves on the Boards and committees of several national and international professional societies, including the American Surgical Association, the Society of American Gastrointestinal and Endoscopic Surgeons, and the Americas Hepato-Pancreato-Biliary Association, among others. At a 2022 American College of Surgeons meeting in Bolivia, he was awarded a Doctor Honoris Causa from University of Aquino. Dr. Asbun is fluent in English and Spanish

Domenech Asbun, M.D., is a hepatobiliary, pancreas and foregut surgeon at Miami Cancer Institute. Dr. Domenech Asbun specializes in minimally invasive surgical procedures to treat liver, pancreatic and upper gastrointestinal diseases. Dr. Domenech Asbun is fluent in English and Spanish and conversational in Italian and Portuguese. Prior to joining Miami Cancer Institute in 2021, Dr. Domenech Asbun completed a fellowship in minimally invasive hepatopancreatobiliary and foregut surgery at the Mayo Clinic Hospital Florida. He has presented at national and international surgical meetings. His research has been published in multiple high-impact surgical journals, including Annals of Surgery and Surgical Endoscopy. He has a strong interest and significant experience in surgical simulation. Dr. Domenech Asbun is passionate about surgery, from the technical aspects to the fulfillment of seeing a patient cured of their complex illness by an operation. His approach to patient care is to treat each patient as a family member when making treatment recommendations. He believes every person deserves high-quality care. When he is not treating patients.

Dr. Osman Ahmed is currently an Associate Professor in the section of Vascular and Interventional Radiology at the University of
Chicago.

He completed medical training at the University of Illinois College of Medicine before attending the University of Chicago for Diagnostic Radiology residency. He subsequently completed his VIR fellowship at Stanford in 2015. Dr. Ahmed has been re cognized as a leader in the community of IR, having recently been selected to attend the SIR’s leadership and development academy and 2020 recipient of the Gary Becker “Young Investigator Award”. He also contributes as Associate Editor for SIR’s flagship editorial, the Journal of Vascular and  interventional Radiology. He has further been recognized by the journal as a Top Reviewer for the years 2016-2020. He is also active as an
Associate Editor for four other journals: the Arab Journal of Interventional Radiology, Applied Radiology, Academic Radiology, and CVIR Endovascular. His clinical and research interests include catheter-based treatments for venous thromboembolism, caval filter retrieval, musculoskeletal interventions, health economics, embolization, and interventional oncology.

Christopher Sinsabaugh, MD is a vascular interventional and abdominal radiologist. He was born in South Bend, IN grew up in Cleveland, OH and returned home to Indiana in the 90s. After serving the United States Marine Corps from 2002-2006, he graduated with a degree in Clinical Laboratory Sciences from IUPUI before attending IU School of Medicine. He completed his residency and fellowship training at the School and now works primarily in pediatric interventional radiology as well as contributing in the adult VIR and abdominal imaging sections. Special interests include irreversible electroporation ablation(IRE), fusion navigation systems, treatment of congenital and acquired vascular malformations, and treatment of tumors (benign and malignant)

Radiology Resident, VU Medisch Centrum Academic Medical Center Amsterdam

Expertise:

RFA, Pancreatic Diseases, Radiofrequency Ablation, Computed Tomography, Magnetic Resonance, Biliary Tract Diseases, Liver Diseases, Cholangiocarcinoma, Interventional Radiology, Angiography

Dr. Mizandari is Head of Diagnostic and Interventional Radiology Department at New Hospitals. With over 30 years of professional experience, he has authored 193 scientific papers. He is the President of the Georgian Association of Cardiovascular and Interventional Radiology and also the Head of Ultrasound Education Center affiliated with the Thomas Jefferson University.

Ahmed Eldefrawy, M.D., is a urologic surgical oncologist at Miami Cancer Institute. Dr. Eldefrawy specializes in treating cancers of the male reproductive organs and male and female urinary tract, including bladder, kidney, testicular adrenal and prostate cancers. He is fluent in English and Arabic. Dr. Eldefrawy joined Miami Cancer Institute from San Diego, where he served as a urologic oncology fellow at the University of California San Diego School of Medicine. His research has been featured in a number of peer-reviewed publications, including Urology, European Urology and Urologic Oncology. He is a member of the American Urological Association and Society of Urologic Oncology and serves as a reviewer for several urology journals, including the Journal of Urology.

Paul Lyons, MD

Dr. Odisio serves as Professor and Co-Director of Research at the Department of Interventional Radiology, Division of Diagnostic Imaging. Dr. Odisio also serves as one of the medical directors of the Image Guided Cancer Therapy (IGCT) Research Program. Dr. Odisio’s main area of clinical practice and research encompass the use of several minimally invasive local therapies for the treatment and palliation of primary and secondary liver malignancies, with an emphasis on the use of percutaneous ablative therapies as a curative-intent treatment option for patients with diverse types of liver cancers. Additionally, Dr. Odisio lab investigates the use of novel advanced imaging method s for improving and predicting outcomes of minimally invasive procedures such as chemoembolization and liver ablation, as well its potential use in combination with hepato-biliary surgical procedures.

Dr. Reto Bale is currently serving as the Associate Professor of Radiology and Head of the Department of Microinvasive Therapy at the Clinic of Radiology, Medical University Innsbruck.
Deputy Chairman Department of Radiology
Chief Division of Interventional Oncology / Microinvasive Therapy
Innsbruck Medical University

http://sip.i-med.ac.at
https://www.linkedin.com/in/reto-bale-a4265631/
https://www.researchgate.net/profile/Reto_Bale
https://orcid.org/0000-0003-0021-5792

Dr. Bradford Wood is Chief of IR and directs a multi-disciplinary team (NIH Center for Interventional Oncology) that develops and translates devices, software, and navigation approaches for cancer patients via novel local and regional minimally invasive, image-guided therapies.

He holds several patents, authored books on radiology and interventional urology, and co-authored more than 600 publications (H-index of 100) including JAMA, NEJM, Nature Communications, Science, Lancet, Blood, Chest, Cancer, JCO, CCR, JAMA Oncology, Hepatology, Medical Physics, and Scientific Reports. Dr. Wood and his team have mentored hundreds of students, fellows, physicians, nurses, and scientists and continue to drive innovation in Interventional Oncology.



Dr. Alda Tam is a tenured Professor in the Department of Interventional Radiology at the University of Texas M.D. Anderson Cancer Center. Dr. Tam earned her undergraduate degree in neuroscience from Brown University, medical degree from the University of British Columbia, and masters in business administration from the University of California, Irvine. She completed her diagnostic radiology residency at the University of Southern California, interventional radiology fellowship at MD Anderson Cancer Center, and subsequently joined the faculty in 2006.  Dr. Tam serves as the Executive Director of Diagnostic Imaging for the MD Anderson Cancer Network and maintains an active interventional radiology practice with involvement in both translational and clinical trials. Dr. Tam is an inducted fellow of the Society of Interventional Radiology (SIR) and American College of Radiology (ACR).  She is the President-Elect of the SIR.

Dr. Caridi was Professor and Chair of the Department of Radiology at the Tulane University Medical Center.  He graduated from Florida State University in 1976 and attended University of Florida College of Medicine. After an internship in Pediatrics at UF followed by Radiology Residency, he returned to the University of Florida as a Fellow in Vascular and Interventional Radiology where he met his lifelong friend, educator and mentor Irwin (Dick) Hawkins, MD, one of the founders of modern Vascular and Interventional Radiology. Jim became part of, and continued the traditions of, that founding legacy.

In 1996, Dr. Caridi became the Chief of the Division of Vascular and Interventional Radiology at UF. He enthusiastically and admirably performed the duties of that key leadership position from 1996 until 2012. During this 16 year tenure as VIR chief Jim continued the legacy of innovation and creativity established by Dr. Hawkins. His publication record, service on editorial boards and in SCVIR as well as funding history by way of creative relationships with innovative medical device companies, reflect his extraordinary devotion to advancing the VIR subspecialty. His joint appointments in the Departments of Surgery and Pediatrics reflect his devotion to the ideals of interdisciplinary cooperation for the benefit of our patients requiring often technically challenging vascular and interventional imaging guided procedures.

In 2015 Dr. Caridi became Professor and Chair of the Department of Radiology at Tulane University Medical Center, a position that he held until his passing. His publication record included 67 peer-reviewed publications and 6 book chapters. He was the recipient of 12 distinguished teaching awards while on the faculty at UF. Jim was voted as a top physician in New Orleans and Louisiana consistently from 2016 to 2019 being recognized as an extraordinarily skilled physician serving those communities. This recognition only touches the surface of his intense dedication to his patients.

Dr. Panoff is a board-certified radiation oncologist at the Miami Cancer Institute and an FIU Herbert Wertheim Medical School Associate Professor. Previously he was an Assistant professor of radiation oncology at the University of Miami Leonard Miller School of Medicine where he taught both residents and medical students. His clinical specialty and research focus is on the use of radiation therapy to treat breast cancer. Dr. Panoff is the recipient of a National Institutes of Health grant to conduct clinical research in pediatric cancer. He is widely published in peer-reviewed medical journals, serves as an editorial reviewer for scientific publications, and is an invited speaker at healthcare symposiums. Dr. Panoff is the Chair of the Institutional Review Board for Research at MCI and the Chair of the Conflict of Interest Review Committee for Baptist Health South Florida. 

Dr. Merve Ozen is a board-certified interventional radiologist and an Assistant Professor of Radiology, Surgery, Obstetrics, and Gynecology at the Department of Radiology, University of Kentucky. Dr. Ozen completed her IR and Advanced IR fellowships at Rush University in Chicago. With a primary focus on liver and bone cancer treatments, as well as pain management through ablation and embolization procedures, she actively practices and conducts research in these fields. Additionally, she volunteers for the Society of Interventional Radiology, contributing to projects that support IR research, increase awareness, and develop online educational resources. Her commitment extends beyond her professional expertise, as she advocates for women in medicine and finds great fulfillment in mentoring aspiring doctors worldwide. 

Robert Suh, M.D. is a Clinical Professor in the Department of Radiological Sciences at the Ronald Reagan UCLA Medical Center and the David Geffen School of Medicine at UCLA. Currently, Dr. Suh serves as the Director of Thoracic Interventional Services and as the Vice Chair of Radiology Education at UCLA Medical Center.  Since 2002, Dr. Suh has been the Program Director of the Diagnostic Radiology Residency. 

Dr. Suh received his BS degree at University of California Riverside and his MD from the David Geffen School of Medicine at UCLA. Following an internship at the University of California Irvine and Long Beach Veterans Administration Medical Center, Dr. Suh completed his training in diagnostic radiology at Loma Linda University Medical Center, followed by fellowships in both vascular interventional radiology and thoracic imaging at Loma Linda University Medical Center and UCLA, respectively. Dr. Suh was the former Director of Thoracic Imaging and Intervention at Loma Linda University Medical Center and was the Acting Chief of Thoracic Imaging at UCLA Medical Center from 2006-2007.

Dr. Suh has focused his research efforts primarily on image-guided thermal ablation, high-dose rate brachytherapy, tissue retrieval, image-guided intratumoral drug delivery and gene profiling technologies in the treatment of pulmonary malignancies, focusing on not only lung cancer but cancer that spreads to the lungs.  

Dr. White is currently a Tenured Professor of Radiology and Surgical Oncology in the Division of Vascular & Interventional Radiology at the Medical College of Wisconsin (MCW), where she has practiced since 2011.  Dr. White was the first in the country to complete the Diagnostic & Interventional Radiology Enhanced Clinical Training Pathway (DIRECT) at the Hospital of the University of Pennsylvania in Philadelphia. Additionally, she received a Master’s Degree in Clinical Investigation from Northwestern University. She founded an Interventional Oncology laboratory focused on translational research developing new techniques and drug-delivery platforms to treat primary and secondary liver cancer at MCW, where she serves as the Vice Chair of Research for the radiology department and Senior Medical Director of Programmatic Excellence, Associate Dean/Assistant Provost of Faculty Affairs. She has received many awards for her research from several national and international organizations, including the Society of Interventional Radiology and the Radiologic Society of North America.

Robert C. G. Martin, II, M.D. PhD, is The Sam and Lolita Weakley Endowed Chair in Surgical Oncology, The Director of the Division of Surgical Oncology, faculty member of the James Graham Brown Cancer Center, and a Professor in the Department of Surgery. He was appointed to the University of Louisville in 2002 as an Assistant Professor and achieved Professor of Surgery in 2011. Dr. Martin received his M.D. from the University of Louisville School of Medicine (1995) and his surgical oncology training and hepato-pancreatico-biliary training from Memorial Sloan-Kettering Cancer Center (2002), and his PhD from the Department of Pharmacology and Toxicology (2008) at the University of Louisville School of Medicine.  

He has completed over 15 prospective clinical trials and principle investigator of 1 Humanitarian Device Exemption (HDE), 2 Investigation New Drugs (IND), and 3 Investigational Device Exemption (IDE) trials. He has completed over 5 NIH funded grants and continues to maintain an active basic science laboratory.

Dr. Martin’s clinical interests are focused on the multi-disciplinary care and surgical management of patients with upper GI malignancies, including esophageal, gastric, duodenal, liver, biliary, and pancreatic cancers. For learn more, visit  https://www.ncbi.nlm.nih.gov/pubmed/?term=(Martin+RC)+and+(louisville)

Bulent Arslan, MD, FSIR, earned his medical degree at Marmara University in Istanbul, Turkey. He completed a residency in diagnostic radiology and a fellowship in vascular and interventional radiology at University of Rochester Medical Center, NY. Before joining Rush in 2012, he served as Associate Professor of Radiology & Interdisciplinary Oncology at University of South Florida College of Medicine, Tampa. Previously, he served as Assistant Professor of Radiology at University of Virginia Health System, Charlottesville, and at University of Arizona, Tucson. He obtained his full professorship in Diagnostic Radiology and Nuclear Medicine at Rush University Medical Center in 2018. He was fellowship program director between 2012 and 2014 at Rush and division director from 2012 to 2022. Currently he is serving as the Chair of newly established Vascular & Interventional Service Line.

Dr Arslan is certified by the ABR in Diagnostic Radiology with CAQ in Vascular & Interventional Radiology. His clinical interests include complex deep venous interventions, aortic and peripheral vascular interventions, aortic and visceral aneurysms and interventional oncology.

An active researcher, Dr. Arslan has participated in more than 30 clinical trials and has authored more than 50 peer-reviewed publications and over 200 scientific abstracts, as well as several book chapters. A frequent speaker, he has been an invited lecturer at more than 200 regional, national, and international medical conferences.

Dr. Arslan is a fellow and member of SIR and also a member of ARRS, RSNA, CIRSE, NANETS, ISNVD, and AMA.

He currently serves as a reviewer for the Journal of Vascular and Interventional Radiology, CardioVascular and Interventional Radiology, and Neurosurgery.

Dr. Haslam is a Consultant Interventional and Uroradiologist based at the Freeman Hospital in Newcastle upon Tyne and is President of the British Society of Interventional Radiology.

He has interests in interventional and uroradiology, with experience in a wide variety of imaging techniques for the kidneys, bladder, prostate gland, arteries and veins.

Dr. Haslam  has been chairman of the British Society of Urogenital Radiology and was a founding member of IOUK (Interventional Oncology UK). He is the founder and Editor in chief of Which Medical Device, an independent educational and review website for medical devices and procedures.

Rupesh Kotecha, M.D., is a board-certified radiation oncologist and Chief of Radiosurgery in the Department of Radiation Oncology and Director of the Central Nervous System (CNS) Metastasis program at Miami Cancer Institute. He is an associate professor in the departments of radiation oncology and translational medicine at the FIU Herbert Wertheim College of Medicine.

He has specialized training and experience in utilizing the latest techniques in radiation therapy for both cancer and noncancerous conditions. His research background and clinical interests have primarily focused on the treatment of patients with stereotactic radiotherapy, including CyberKnife, LINAC-based, and GammaKnife radiosurgery, and stereotactic body radiation therapy (SBRT) or stereotactic ablative radiotherapy (SABR). He also specializes in advanced radiation therapy treatment techniques, including re-irradiation, proton beam radiotherapy, and MR-guided radiation therapy.

During medical school, Dr. Kotecha was inducted into the Alpha Omega Alpha Honor Medical Society, an organization that recognizes excellence in scholarship and the profession of medicine. He has been an invited speaker at numerous national and international symposiums, and has published multiple book chapters and over 100 manuscripts in peer-reviewed journals. His research bandwidth spans investigator-initiated studies to multi-center trials to national cooperative group clinical protocols. Dr. Kotecha serves as the CNS co-chair for the Proton Collaborative Group, coordinates the NCI Glioblastoma Clinical Interest Group, and is a course director for the annual Miami Brain Symposium. He is an editorial contributor and advisory board member on the topic of brain cancer for Practice Update, an online resource for healthcare providers throughout the United States and around the world.

Procedures Performed:

3-D conformal radiotherapy

Brachytherapy

External beam radiotherapy

Gamma Knife radiosurgery

Cyberknife radiosurgery

Image-guided radiation therapy

Intensity modulated radiation therapy

Stereotactic body radiotherapy

Stereotactic ablative radiotherapy

Re-irradiation

Spatially fractionated radiotherapy

MR-guided radiotherapy

Proton beam radiotherapy

Cardiac radiosurgery

Education, Fellowship, & Training
Medical School- Michigan State University College of Human Medicine, East Lansing, Mich.
Residency – Radiation Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio

Peter Littler is a Consultant Interventional Radiologist with an interest in Interventional Oncology, leading a regional service for liver ablation, TACE and SIRT. Peter is the Secretary of IOUK and was the Chair of the Scientific Programme Committee for BSIR Annual Scientific Meeting 2021.

Graham Munneke is a consultant interventional radiologist at University College London Hospitals.  He qualified from St George’s Hospital Medical School and after gaining membership to the Royal College of Physicians and Fellowship of the Royal College of Radiologists he subsequently subspecialised in Interventional Radiology.

Graham is the past chairman of the research and registries committee of the British Society of Interventional Radiology.  He currently sits on the management committee of the European CIRT registry looking at patients treated with radio-embolisation across Europe.  He has been a   special advisor to NICE for radio-embolisation and was a member of the NHS England Commissioning through evaluation SIRT committee.

Graham is the author of several peer-reviewed papers and has lectured at National and International level on targeted oncological therapies.

Dr. Nutting is internationally renowned for his image guided liver cancer and embolization therapies. Practicing for more than 25 years, he is best known for liver cancer therapies, having performed more than 5,000 Y90 radioembolizations, bland and chemo-embolization of liver tumors.

He is also an expert in prostate artery embolization (PAE) having treated more than 600 patients over the last 10 years. He trained with the experts in Portugal and Brazil; and is nationally recognized for training other physicians around the country. Dr Nutting has transitioned his hospital based practice to the office-based lab (OBL) over the last 3 years.

Dr. Siddharth Padia is an Interventional Radiologist and Professor of Radiology at the David Geffen School of Medicine at UCLA. He is also director of Interventional Radiology at UCLA Santa Monica. His areas of clinical expertise and research interests include liver cancer, interventional oncology, vascular disease and portal hypertension.

Dr. Padia earned his medical degree from Johns Hopkins University School of Medicine. After completing his transitional internship at The University of Hawaii in Honolulu, Dr. Padia began his residency in diagnostic radiology at the Cleveland Clinic in Ohio and graduated as Chief Resident. After spending many years practicing interventional radiology at the University of Washington, Dr. Padia joined the faculty at UCLA in 2016.

Dr. Padia specializes in advanced minimally-invasive technologies to treat liver cancer by infusing highly radioactive particles (Yttrium-90) into the liver, and has treated over 800 patients with this therapy. Due to his expertise in this field, he is the primary author of the national treatment guidelines for Yttrium 90 radioembolization, and is a director of the national annual course to educate physicians on this therapy. Recently, he has helped develop novel treatments for patients suffering from knee arthritis, specifically genicular artery embolization. He has recently led and completed the largest US clinical trial to date for genicular artery embolization, and is embarking on multiple trials for embolization of joint pain.

Constantino S. Peña, MD is an interventional radiologist at the Miami Cardiac and Vascular Institute at Baptist Hospital in Miami Florida where he also serves as the Medical Director of Vascular Imaging. Dr. Peña earned his B.S. and M.S. from the Stanford University Department of Biology in Palo Alto, Calif., prior to earning his medical degree from the Yale University School of Medicine in New Haven, Conn. He completed his residency in Diagnostic Radiology in 1999 as well as a Vascular and Interventional fellowship in 2000 at Massachusetts General Hospital in Boston, Mass. An educator, Dr. Peña is also a Clinical Assistant Professor of Radiology at the Florida International University College of Medicine in Miami as well as a Collaborative Associate Professor of Radiology at the University of South Florida College of Medicine in Tampa, Florida. He is on the Annual Meeting Committee of the SIR. He has served as the Chair of the Cardiovascular Radiology & Intervention Council of the American Heart Association (AHA) and a board member of the IAC CT. He has served on several committees for many professional organizations, including the RADInfo Committee of the ACR and RSNA, the Society of Interventional Radiology (SIR) IO service line, and the Vascular and Interventional Subcommittee Scientific Program Committee (SPC) for the Radiological Society of North America (RSNA). Dr. Peña is a fellow of the SIR, AHA, and SCCT.

Luis E. Raez, M.D., FACP, FCCP; is the President of the Florida Society of Clinical Oncology (FLASCO). He works as Chief Scientific Officer & Medical Director of Memorial Cancer Institute (MCI), he is also Director of the Thoracic Oncology Program.

He is Co-Director of the MCI/FAU Florida Cancer Center of Excellence designated by the Florida governor, one of the 5 centers in Florida. He is also Clinical Professor of Medicine at FIU, Visiting Professor of Medicine at Cayetano Heredia University in Peru and Associate Professor of Clinical Biomedical Science for FAU. He was also faculty at Sylvester Cancer Center/University of Miami for 10 years (2001-2011).

He has expertise in medical oncology in the areas of lung cancer, and head and neck cancer. He designs phase I-III clinical trials with new chemotherapeutic agents and combinations. He has given oral presentations in 5 continents. He is American Board Certified in: Internal Medicine and Medical Oncology. He is board eligible in Hematology.

Dr. Rocha is the Hugh and Georgeina Hedinger Chair of Surgical Oncology at Oregon Health and Science University (OHSU) in Portland, OR. He also serves as the Physician-in-Chief of the Knight Cancer Institute at OHSU. He graduated with honors from the University of Chicago Pritzker School of Medicine. After training in general surgery at the Brigham and Women’s Hospital and Harvard Medical School both in Boston, he completed both a surgical oncology and hepatopancreatobiliary surgery fellowship at Memorial Sloan-Kettering Cancer Center in New York.  Dr. Rocha’s clinical practice encompasses all aspects of benign and malignant disease of the liver, bile ducts and pancreas. He has been funded by the AAS, NIH/NIDDK, ASCO and the Cholangiocarcinoma Foundation. Dr. Rocha currently sits on the editorial boards of Surgery, HPB, Annals of Surgical Oncology, and Journal of Surgical Oncology. He has served on the NCI Pancreas Task Force, ASCO Gastrointestinal Cancers Advisory Council and ASTRO Liver Cancer Guidelines Committee.  He is currently the surgical lead of the International Cholangiocarcinoma Research Network (ICRN), Vice-Chair of the Southwest Oncology Group (SWOG) Surgery Committee, GI Surgery Working Group Chair at Eastern Cooperative Group (ECOG-ACRIN) and Secretary/Treasurer of the North Pacific Surgical Association.

MBBS, MD – Radio Diagnosis/Radiology

Radiologist

26 Years Experience Overall  (21 years as specialist)

Medical Registration Verified

Dr. Aniruddha Kulkarni is a Radiologist and has an experience of 26 years in this field. He completed MBBS from Government Medical College, Aurangabad Maharashtra in 1995 and MD – Radio Diagnosis/Radiology from Government Medical College, Aurangabad Maharashtra in 1999.
He is a member of Indian Medical Association (IMA),IRIA and Indian Federation of Ultrasound in Medicine and Biology (IFUMB). Some of the services provided by the doctor are: Vascular Imaging,General Radiology and Teleradiology etc.

Associate Prof

Radiation Oncology

Tata Memorial Centre Advanced Centre for Treatment, Research and Education in Cancer
India

Biography
2013 has seen the institution expand its activities outside its traditional bastion of Mumbai with projects at Vizag, Chandigarh, Sangrur, in addition to the cancer registries that are being setup all over the country. This notwithstanding, there has been a lot of activity at Parel as well, towards our mission of providing the best cancer care to all who seek treatment at the hospital. We are constantly mindful of the fact that the existing infrastructure at the hospital is stretched given the patient load. The majority of our efforts and initiatives are therefore directed at being patient friendly.Towards these goals we augmented our semiprivate bed strength where wait lists were over 6- 8 weeks by converting the old private wards in the main building to semi private accommodation. The private rooms are now exclusively housed in the new Homi Bhabha block. This helps in accommodating more patients while maintain the 60:40 general to private ratio. Our smart card transactions have now been expanded to cover the inpatient services and the general category patients as well. The smart card ensures that all services at the hospital are now cashless, saving time patients spent in long queues. In addition, smart card kiosks are setup all over the outpatient areas to help patients to check balances, expenditures, deposits as well as status of their reports. Patients now also get SMS alerts of their smart card transactions. Towards a green environment our paperless operations have been expanded with no printing of patient reports and pharmacy memos. Patients can however view and prints reports at any time from any location as these are available on the web with restricted access only to the patient and his / her treating clinician.Infrastructure has been augmented with the installation of high value equipment that includes a digital mammography, augmentation of the minimal invasive surgical capabilities, surgical microscopes and anesthesia delivery systems.There has been a major revamp of the hospital Institutional Review Board with space allocated for a dedicated trial pharmacy. In addition, our pediatric ward and outpatient clinic have had a major revamp through a generous philanthropic gesture, making it more child friendly for our young patients. Our service to the Rajiv Gandhi Jeevan Arogya Yojana for patients below the poverty line initiated by Government of Maharashtra has been well appreciated, with the hospital recognized as the leader in the care of cancer patients under this scheme.A financial management system with the help of the ECIL is also fully implemented putting inplace greater accountability and ease in our accounting process. These efforts are reflected in the fact that we have won the best Oncology hospital award by CNBC – ICICI Lombard for the 4th year in running. I place on record the contribution of each and every one of our staff who many a time, work well beyond the call of normal duty.

Research Interest

Oncology

Gloria L. Hwang, MD, FSIR, is Clinical Professor of Radiology at Stanford. Her clinical interests include interventional oncology, portal hypertension, and biliary interventions. She also serves as the Associate Chair of Clinical Performance Improvement, Associate Program Director for the Department of Radiology, and chairs the Radiology IT Operations Committee; in those roles, she leads projects and programs to support radiologists to perform at their best.

Charles Jonathan Lugo, MD is a diagnostic radiologist in Stony Brook University, NY specializing in diagnostic radiology. He graduated from University of Wisconsin School of Medicine and Public Health in 2014 and has 8 years of experience. Charles Jonathan Lugo, MD is affiliated with Stony Brook Medicine.

Dr. David S. Lu is a UCLA Health radiologist with a unique blend of training and interests that focus on cancer in a field called interventional oncology. Patients who work with Dr. Lu receive new imaging from a specialist point of view, with recommendations for the most minimally invasive therapies possible to treat their cancer. Get to know Dr. Lu: https://www.uclahealth.org/david-lu Book an appointment: 310-301-6800 More info: https://www.uclahealth.org/radiology

Robert Suh, M.D. is a Clinical Professor in the Department of Radiological Sciences at the Ronald Reagan UCLA Medical Center and the David Geffen School of Medicine at UCLA since 1998. Currently, Dr. Suh serves as the Director of Thoracic Interventional Services and as the first Vice Chair of Radiology Education at UCLA Medical Center since 2016.  Dr. Suh is the current and has been Program Director of the Diagnostic Radiology Residency since 2002.

Dr. Suh received his BS degree at University of California Riverside and his MD from the David Geffen School of Medicine at UCLA. Following an internship at the University of California Irvine and Long Beach Veterans Administration Medical Center, Dr. Suh completed his training in diagnostic radiology at Loma Linda University Medical Center, followed by fellowships in both vascular interventional radiology and thoracic imaging at Loma Linda University Medical Center and UCLA, respectively. Dr. Suh was the former Director of Thoracic Imaging and Intervention at Loma Linda University Medical Center and was the Acting Chief of Thoracic Imaging at UCLA Medical Center from 2006-2007.

Dr. Suh’s clinical practice for over 20 years centers on interpreting diagnostic imaging of the lung and performing image-guided procedures within the lung and chest cavity, which include precision lung biopsies for diagnosis and treatment selection to fully enable personalized medicine for patients and thermal ablation of lung tumors utilizing microwave energy and cryotherapy. He is part of UCLA’s faculty that have pioneered and developed the discipline of Interventional Oncology on national and international levels. The Thoracic Interventional Services at UCLA Radiology is one of the most experienced centers specializing in lung procedures in the country, and over the past two decades, Dr. Suh is an internationally recognized leader in lung thermal ablation.

Dr. Suh has focused his research efforts primarily on image-guided thermal ablation, high-dose rate brachytherapy, tissue retrieval, image-guided intratumoral drug delivery and gene profiling technologies in the treatment of pulmonary malignancies, focusing on not only lung cancer but cancer that spreads to the lungs.  His collaborative efforts occur with his colleagues within the Thoracic Imaging Research Core in diffuse lung disease, pulmonary nodule characterization and biopsy technology, and with corresponding subspecialty colleagues, in lung cancer. Over his career, Dr. Suh has moderated and given over 500 presentations at local, regional, national and international meetings, conferences and congresses.